Kyverna Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
149
- Stock Symbol
-
KYTX
- Share Price
-
$5.05
- (As of Friday Closing)
Kyverna General Information
Description
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
Contact Information
Website
www.kyvernatx.comCorporate Office
- 5980 Horton Street
- Suite 550
- Emeryville, CA 94608
- United States
Corporate Office
- 5980 Horton Street
- Suite 550
- Emeryville, CA 94608
- United States
Kyverna Timeline
Kyverna Stock Performance
As of 13-Nov-2026, Kyverna’s stock price is $5.05. Its current market cap is $319M with 63.2M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.05 | $5.03 | $4.50 - $13.67 | $319M | 63.2M | 861K | -$2.76 |
Kyverna Financials Summary
As of 30-Sep-2026, Kyverna has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 254,106 | 394,188 | (150,989) | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (161,693) | (168,113) | (140,561) | (60,754) |
| Net Income | (157,792) | (161,307) | (127,477) | (60,366) |
| Total Assets | 189,437 | 293,826 | 304,645 | 75,195 |
| Total Debt | 32,452 | 29,032 | 8,242 | 9,079 |
Kyverna Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kyverna Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Kyverna Comparisons
Industry
Financing
Details
Kyverna Competitors (4)
One of Kyverna’s 4 competitors is Sangamo Therapeutics, a Formerly VC-backed company based in Richmond, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Cabaletta Bio | Formerly VC-backed | Philadelphia, PA | ||||
| Quell Therapeutics | Venture Capital-Backed | London, United Kingdom | ||||
| Artax Biopharma | Venture Capital-Backed | Cambridge, MA |
Kyverna Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Kyverna Patents
Kyverna Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024369476-A1 | Methods for manufacture of engineered t cells from whole blood samples | Pending | 03-Nov-2023 | ||
| EP-4802060-A1 | Methods for manufacture of engineered t cells from whole blood samples | Pending | 03-Nov-2023 | ||
| WO-2025097034-A1 | Methods for manufacture of engineered t cells from whole blood samples | Inactive | 03-Nov-2023 | ||
| EP-4801545-A1 | Methods for treating multiple sclerosis and other autoimmune diseases using anti-cd19 car-t cell therapies | Pending | 31-Oct-2023 | ||
| WO-2025096818-A1 | Methods for treating multiple sclerosis and other autoimmune diseases using anti-cd19 car-t cell therapies | Inactive | 31-Oct-2023 | A61K40/31 |
Kyverna Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Kyverna Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kyverna ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.09 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Kyverna FAQs
-
When was Kyverna founded?
Kyverna was founded in 2018.
-
Where is Kyverna headquartered?
Kyverna is headquartered in Emeryville, CA.
-
What is the size of Kyverna?
Kyverna has 149 total employees.
-
What industry is Kyverna in?
Kyverna’s primary industry is Biotechnology.
-
Is Kyverna a private or public company?
Kyverna is a Public company.
-
What is Kyverna’s stock symbol?
The ticker symbol for Kyverna is KYTX.
-
What is the current stock price of Kyverna?
As of 13-Nov-2026 the stock price of Kyverna is $5.05.
-
What is the current market cap of Kyverna?
The current market capitalization of Kyverna is $319M.
-
Who are Kyverna’s competitors?
Sangamo Therapeutics, Cabaletta Bio, Quell Therapeutics, and Artax Biopharma are competitors of Kyverna.
-
What is Kyverna’s annual earnings per share (EPS)?
Kyverna’s EPS for 12 months was -$2.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
